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Abstract
Intravenous lipid emulsion is an established, effective treatment for local anesthetic-induced cardiovascular collapse.
The predominant theory for its mechanism of action is that by creating an expanded, intravascular lipid phase,
equilibria are established that drive the offending drug from target tissues into the newly formed ‘lipid sink’. Based
on this hypothesis, lipid emulsion has been considered a candidate for generic reversal of toxicity caused by over-
dose of any lipophilic drug. Recent case reports of successful resuscitation suggest the efficacy of lipid emulsion
infusion for treating non-local anesthetic overdoses across a wide spectrum of drugs: beta blockers, calcium chan-
nel blockers, parasiticides, herbicides and several varieties of psychotropic agents. Lipid emulsion therapy is gaining
acceptance in emergency rooms and other critical care settings as a possible treatment for lipophilic drug toxicity.
While protocols exist for administration of lipid emulsion in the setting of local anesthetic toxicity, no optimal regi-
men has been established for treatment of acute non-local anesthetic poisonings. Future studies will shape the
evolving recommendations for lipid emulsion in the setting of non-local anesthetic drug overdose.
Introduction
Intravenous lipid emulsion (ILE) is a novel method for
treating local anesthetic systemic toxicity (LAST) that
also shows promise as an effective antidote for other lipo-
philic drug poisonings. Cardiovascular collapse is the
most life-endangering complication of local anesthetic
(LA) absorption or intravascular injection during regional
anesthesia [1]. LAST is generally considered to be resis-
tant to conventional modes of resuscitation. However, in
1998, Weinberg et al. reported the effective use of a lipid
emulsion infusion in resuscitation of bupivacaine over-
dose in rats [2]. Follow up studies in dogs confirmed the
efficacy of ILE in treating an otherwise fatal overdose of
bupivacaine, even after an interval of 20 minutes [3].
Subsequent case reports demonstrated rapid reversal of
LAST with use of ILE often after standard resuscitative
efforts had failed [4,5]. Lipid therapy has also been
utilized in patients suffering from poisonings other than
those involving LA toxicities [6,7]. Recent research has
focused on the efficacy of lipid emulsion in resuscitating
patients from overdoses of lipophilic, non-LA agents.
This article focuses on the history of lipid resucitation, its
theorized mechanisms of action, and its use in local and
non-LA drug overdoses. Relevant articles were gathered
by the authors’ independent searches of multiple biblio-
graphic databases. Administration of any formulation of
ILE and a range of outcome measures (mortality, hemo-
dynamics, mental status, cardiac function, adverse effects)
were considered.
Last: Discovery and Evolution of ILE
Development of ILE
Cardiotoxicity resulting from bupivacaine and other
local anesthetics has been the subject of laboratory
investigation for over three decades. Long acting lipo-
philic local anesthetics such as bupivacaine and etido-
caine were implicated in several fatal cardiac arrests
reported in 1979 by Albright [8]. These events all
appeared to resist standard forms of resuscitation. ILE
was initially identified as an antidote for LAST, the
most feared complication of regional anesthesia. In
1997, Weinberg et al. described a patient with severe
carnitine deficiency who suffered a cardiac arrest from
only 22 mg of bupivacaine administered subcutaneously
with injection of tumescent solution during a general
anesthetic [9]. This case led to studies of the potential
interaction of bupivacaine and elements of the carnitine
cycle that later confirmed bupivacaine potently inhibits
the mitochondrial enzyme carnitine-acylcarnitine trans-
locase [10]. This observation led to animal studies that
ultimately identified the benefit of ILE resuscitation.
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lipid became resistant to bupivacaine-induced cardiac
effects, as a larger dose of bupivacaine was required to
induce asystole [2]. Additional dose-response experi-
ments in the same study found that when 20% lipid
emulsion was given during resuscitation after the intra-
venous bupivacaine bolus dose (post-treatment) the
LD50 of bupivacaine was increased from 12.5 mg/kg to
18 mg/kg. Moreover, the survival curves were suffi-
ciently shifted at a bupivacaine dose of 15 mg/kg, where
all control animals died while no deaths occurred in
those animals given ILE. This observation suggested a
potential for using ILE in treatment of cardiotoxicity
resulting from local anesthetic toxicity. Follow-up
experiments in the Weinberg lab examined the efficacy
of ILE in anesthetized dogs after an intravenous over-
dose of bupivacaine (10 mg/kg) [3] [figure 1]. Resuscita-
tion comprised open-chest cardiac massage with or
without a 20% lipid infusion. All dogs receiving lipid
infusion recovered normal blood pressure and EKG
traces, while all control animals died.
Optimization Studies and Remaining Questions
Investigations in the past several years have focused
attention on the merits of ILE in the setting of stan-
dard resuscitation protocols. Weinberg et al studied
lipid compared to epinephrine in a rat model of bupi-
vacaine-induced cardiac arrest [11]. Ten minutes after
initiating the resuscitation, the mean rate pressure pro-
duct (RPP, systolic pressure × heart rate) in the lipid
group was significantly greater than that in the epi-
nephrine-treated group, which was no different than
that of the saline controls. Moreover, the epinephrine-
treated groups had worse metabolic indicators of
recovery: the pH, PaO2, and SvO2 were all lower in
the epinephrine group, and lactate levels were higher.
Pulmonary edema occurred almost immediately in four
of the five epinephrine-treated rats, but in none in the
lipid group.
A follow-up study compared recovery following bupi-
vacaine overdose in rats treated with ILE versus vaso-
pressin either alone or combined with epinephrine [12].
ILE was more effective than either of the other treat-
ments. Specifically, hemodynamic and metabolic para-
meters measured at 15 minutes, (five minutes after
cessation of resuscitation) indicated a poor quality of
recovery in all rats receiving vasopressin, with or with-
out epinephrine. Metrics of tissue perfusion (e.g., central
venous oxygen tension and blood lactate concentration)
were particularly adversely affected by vasopressin.
Moreover, lung wet-to-dry ratios were higher among the
groups that received vasopressin compared with the ILE
cohort, implying permeable increases in lung parench-
yma and potential structural damage. A study of the
dose-response to epinephrine during lipid treatment of
bupivacaine overdose in rats indicated that while epi-
nephrine routinely resulted in more rapid return of RPP
than lipid (only) in the first few minutes of resuscitation,
by the experiment’s end, animals that had received 10
mcg/kg or more of epinephrine experienced substantial
decline in all hemodynamic and metabolic parameters
[13]. In addition, it was clear that high systolic pressures
early in the resuscitation did not imply successful resus-
citation by 15 minutes, at which time lipid-treated sub-
jects exhibited better recovery profiles than those given
the higher doses of epinephrine. These three studies beg
t h es a m eq u e s t i o n :“Is lipid emulsion superior to stan-
dard resuscitation protocols for cardiac arrest attributa-
ble to local anesthetic toxicity”? If so, does it follow that
one should avoid or modify the recommendations for
Figure 1 BP during a typical experiment. B indicates the start of a bupivacaine 10 mg/kg bolus. This is taken as zero time. Criteria for
circulatory collapse were reached at 4.5 minutes, and internal cardiac massage (indicated by C) was begun, causing the subsequent pressure
spikes that continued until shortly after the lipid infusion (indicated by L), which began at 15 minutes. Circulation was sufficiently established by
26 minutes (after roughly 10 minutes of lipid therapy), when isoflurane general anesthesia was restarted (indicated by I).
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toxicity or other lipophilic drug overdoses, opting
instead to use ILE alone as first-line treatment or
resuscitation?
A study by Mayr et al [14] challenges the use of ILE
compared with vasopressor treatment in bupivacaine
overdose. In a porcine model, Mayr et al demonstrated
that vasopressin plus epinephrine led to higher coronary
perfusion pressure and better short-term survival as com-
p a r e dt ol i p i di n f u s i o n[ 1 4 ] .H o w e v e r ,i nt h i sm o d e l
mechanical ventilation was discontinued after the injec-
tion of bupivacaine (5 mg/kg) and apnea was maintained
until asystole occurred plus an additional minute. There-
fore it is possible that the asphyxia was a confounding
factor that diminished efficacy of the ILE and influenced
the authors’ interpretation of the data that vasopressor
therapy is more effective than lipid. Similarly, in 2009
Hicks et al [15] demonstrated in a swine model, that lipid
emulsion combined with epinephrine and vasopressin
did not improve survival or hasten return of spontaneous
circulation. However, these animals all received massive
doses of epinephrine and vasopressin during a resuscita-
tion interval of ten minutes prior to receiving the test
treatments. Findings published from the Weinberg lab
predict exactly this finding: that lipid emulsion may show
little or no benefit when the subject has also received
large vasopressor doses [13]. The cardiac anatomy and
physiology of swine differs from canines and these
species-specific differences might also contribute to the
diminished effect of lipid emulsion in the setting of bupi-
vicaine toxicity [16]. The optimal model for assessing
treatment of bupivacaine toxicity will need to be identi-
fied for future studies to offer a more complete under-
standing of this phenomenon.
ILE in Last
Many case reports [17-21] and animal studies [2,3,11,22]
describe the successful use of ILE to reverse local anes-
thetic toxicity, which can present with neurologic symp-
toms with or without cardiovascular instability. One of
the earliest cases describes the accidental injection of
40 ml of 1% ropivicaine for an axillary plexus block in
an 84-year-old woman [20]. Shortly after the block was
placed, the patient developed generalized tonic-clonic
seizures followed by asystole. Standard resuscitation
measures were unsuccessful and after 10 min of cardio-
vascular collapse, lipid emulsion was given by a bolus
followed by an infusion. Normal EKG rhythm returned,
and blood pressure was restored to normal; the patient
was discharged to home in four days with near complete
recovery. This sequence is typical of successful ILE:
rapid reversal of toxicity after standard measures have
failed. McCutchen et al [23] described the co-adminis-
tration of standard ACLS drugs and ILE to rescuscitate
an 82 year old woman who underwent sciatic block
placement immediately after uneventful femoral nerve
catheter placement and bolus. Within twenty seconds of
bupivacaine injection for the sciatic block, the patient
suffered a general clonic-tonic seizure which responded
to midazolam. A patent airway was maintained, but the
patient’s rhythm converted to ventricular tachycardia
and did not respond immediately to a single dose of
amiodarone followed by a single lipid bolus. Ventricular
tachycardia persisted for several minutes and one coun-
tershock was given followed by a continuous lipid infu-
sion. Although initially obtunded, after two hours of
infusion the patient’s mental status returned to normal.
The authors attribute the full recovery and the avoid-
ance of cardiovascular collapse to rapid administration
of lipid.
Cardiac toxicity is at times preceded by CNS symp-
toms and some physicians have chosen to administer
ILE earlier in the progression of the toxicity syndrome.
Many case reports describe the use of ILE prior to the
onset of cardiovascular collapse [17,19,20,23]. For
instance, Foxall et al [18] described the use of ILE to
treat CNS toxicity and ventricular ectopy in an effort to
prevent the progression to cardiac arrest. In another
case, a 13 year old girl developed ventricular tachycardia
after a lumbar plexus block with ropivicaine-lidocaine
[24]. ILE was administered at the onset of this arrhyth-
mia and normal vital signs were quickly restored. The
EKG returned to baseline and surgery proceeded
uneventfully. The evidence for efficacy of ILE’s ability to
reverse cardiac local anesthetic toxicity continues to
mount.
Mechanism of Action of ILE
Lipid Sink Phenomenon
The solubility of long-acting local anesthetics in lipid
emulsion and the high binding capacity of these emul-
sions likely explain the clinical efficacy when lipid is
rapidly infused in cases of LAST. Initially coined in
1998 by Weinberg [2], the ‘lipid sink’ phenomenon is
the most widely accepted mechanism of action for ILE.
Lipid emulsion infusion creates an expanded lipid phase,
and the resulting equilibrium drives toxic drug from tis-
sue to the aqueous plasma phase then to the lipid phase.
While the exact mechanisms of action of lipid emul-
sion infusion to treat LAST remain unclear, the key
component is likely the binding property of the emul-
sion [25]. The 20% Intralipid™(Kabivitrum Inc., Califor-
nia, USA) emulsion consists of 20% soybean oil, 1.2%
egg yolk phospholipids, 2.25% glycerin, water and
sodium hydroxide. Although Intralipid™is the most com-
mon commercial preparation used in documented resus-
citations, there are many different ILE products with
different formulations. It is nonetheless the emulsified
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lipophilic substances are theoretically partitioned, when
infused into an aqueous medium such as blood. Lipo-
philic substances, such as local anesthetics, are drawn
into the “lipid sink” and a concentration gradient devel-
ops between tissue and blood which cause local anes-
thetics to move away from the heart or brain (areas of
high concentrations) to the “lipid sink”.I na ne x p e r i -
mental rat model, Weinberg et al demonstrated that
radiolabeled bupivacaine added in vitro to lipid-treated
rat plasma preferentially moves to the lipid phase with a
partition coefficient of 11 [2]. In subsequent experi-
ments using an isolated heart model of bupivacaine toxi-
city, Weinberg et al showed that infusion with lipid
emulsion accelerates the removal of radiolabeled bupiva-
caine from myocardial tissue compared with controls
[26] [figure 2].
Alternate Mechanisms
Lipid emulsion could theoretically increase intracellular
fatty acid content and therefore overcome the reduced
ATP production, which results from LA block of fatty
acid transport and oxidation. It is possible that the
resulting increased intracellular fatty acid content con-
tributes to improved ATP synthesis in the cardiomyo-
cyte. Under normal aerobic conditions, fatty acids are
the preferred substrate for myocyte oxidative phosphor-
ylation, generating about 80-90% of cardiac adenosine
triphosphtae (ATP) [27]. If fatty acid transport is inter-
rupted, then ATP production decreases, negatively
impacting myocyte survival and potentially leading to
cardiac toxicity. Van de Velde et al [28] used a dog
model to demonstrate that infusion of 20% lipid emul-
sion improves contractility because of improved fatty
acid oxidation. Another study performed by Eledjam
et al [29] showed that pre-incubation with ATP in iso-
lated myocardial strips prevents depression of contracti-
lity by bupivacaine. Therefore, ILE may increase
intracellular fatty acid content enough to reverse or
overcome the decrease in cardiac ATP synthesis.
Interestingly, lipid emulsion was initially observed as
acting faster in vivo settings than was anticipated based
on a simple lipid sink mechanism, implying that direct
cardiotonic effects might also be at play [30]. Stehr et al
[31] demonstrated that lipid emulsion reverses bupivi-
caine-induced contractile depression at concentrations
that are too low to provide a lipid sink phenomenon,
suggesting a metabolic explanation for the positive
effect. Lipid emulsion infusion might also directly
increase intramyocyte calcium levels and lead to a direct
positive inotropic effect [32]. Fatty acids have also been
shown to increase calcium levels in cardiac myocytes.
Although the precise mechanisms of action of ILE treat-
ment of LAST requires further elucidation, the key com-
ponent is likely due to the efficient binding properties of
the emulsion.
ILE in Non-LA Drug Toxicity
Lipid emulsion therapy has not been limited to the
treatment of local anesthetic toxicity. Because of recent
human case reports of successful resuscitation, there has
been increasing interest in the potential benefit of lipid
Figure 2 Cardiac bupivacaine content. The trends for myocardial bupivacaine content are shown during the 2 minutes after a 30-second
infusion of bupivacaine 500 μmol/L for control and lipid-treated hearts. Values are normalized to zero time, and error bars indicate standard
deviation (n = 5 for both groups). Regression curves were fitted by single exponential decay functions with time constants 83 seconds (R
2 =
0.9861) and 37 seconds (R
2 = 0.9978) for control and lipid groups, respectively.
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non-LA drugs [33,34]. Two comprehensive literature
reviews describe the use of ILE in the setting of non-LA
overdoses [35,36]. Recent case reports of successful
resuscitation suggest the efficacy of lipid emulsion infu-
sion for treating non-local anesthetic overdoses across a
wide spectrum of drugs: beta blockers, calcium channel
blockers, parasiticides, herbicides and several varieties of
psychotropic agents. The most clinically relevant of
these are likely to be toxicities caused by tricyclic anti-
depressants and other psychotropic drugs, calcium chan-
nel blockers and beta blockers. These medications share
similar sodium channel blocking properties with local
anesthetics and are generally quite lipophilic. Presum-
ably, ILE exerts the same “lipid sink” effect with these
lipophilic drugs, thereby decreasing the amount of active
drug in the target tissue and reducing toxicity [37].
Psychotropic Drugs
Yoav et al [38] showed decreased mortality in rats when
clomipramine was administered in a lipid infusion vehicle
versus saline. Harvey and Cave [39] used a rabbit model
to study the effects of lipid infusion for clomipramine
toxicity and found faster recovery from hypotension in
lipid-treated rabbits compared to saline or sodium bicar-
bonate treated controls. A rat model of amitriptyline
toxicity failed to find statistically significant differences in
hemodynamic parameters or survival, but these findings
may be explained by the small sample size [40].
The first report of lipid emulsion’s successful use in a
human as an antidote for a lipophilic, non-local anes-
thetic toxicity was by Sirianni et al [6]. They describe
the resuscitation of a 17 year old female after massive
ingestion of bupropion and lamotrigine, prescribed for
the treatment of depression and bipolar disorder. Ten
hours later, the patient experienced complete cardiovas-
cular collapse with ventricular fibrillation and pulseless
electrical activity. After seventy minutes of unsuccessful
resuscitation using standard ACLS plus sodium bicarbo-
nate injection, 20% ILE was given as a last attempt to
restore hemodynamic stability. Within one minute of
ILE administration normal vital signs were re-estab-
lished. She recovered and was discharged from the hos-
pital with minimal neurologic deficits.
A case report in Anaesthesia described the use of ILE
in a 61 year old male who intentionally ingested toxic
levels of quetiapine and sertraline, a protein bound drug
that is susceptive to ILE effects due to its high lipid par-
tition co-efficient [41]. The patient presented to the
emergency department with a Glasgow coma scale of 3
and in normal sinus rhythm with no QT prolongation,
but hypotensive. Approximately four hours after inges-
tion, 20% lipid emulsion was given at a bolus dose of
1.5 mL/kg; within fifteen minutes, a rapid increase in
the patient’s level of consciousness was observed, to a
GCS of 9, negating the need for intubation in this
patient. All vitals were within normal ranges within
12 hours of admission, and the patient was subsequently
discharged.
Weinberg et al [7] reported a case of successful resus-
citation of a patient with haloperidol induced cardiac
arrest. The patient was admitted to the hospital with an
underlying prolonged QT interval on electrocardiogram
and developed ventricular bigeminy with pulseless mul-
tiform ventricular tachycardia after haloperidol adminis-
tration. After administration of lipid emulsion therapy,
the patient’s rhythm was restored; she was completely
alert and oriented 18 hours after the event.
Calcium Channel Blockers (CCBs)
Multiple animal trials have demonstrated the benefits of
ILE versus placebo in verapamil toxicity [42]. Tebbutt
et al [42] showed in 2006 that the use of lipid emulsion
almost doubled the LD50 and attenuated the bradycardia
seen with toxic doses of verapamil in rats. Bania et al [43]
subsequently evaluated lipid emulsion compared to stan-
dard resuscitation techniques in a canine model of vera-
pamil toxicity and found that ILE-treated animals had
significantly higher MAPs at 30, 45, and 60 minutes post-
rescue compared to control dogs. A confirmation of effi-
cacy for ILE in treating CCB overdose was provided by
Young et al [44] who published the first human case of
verapamil toxicity successfully treated with lipid emul-
sion. Their patient was in shock that was refractory to
standard resuscitation therapy but resolved with adminis-
tration of intravenous lipid emulsion; no adverse events
were noted and full patient recovery ensued. Other case
reports relate similar hemodynamic improvement in
patients with calcium channel blocker overdoses [45,46].
Beta Blockers
In both rat and rabbit models, ILE mitigates propanolol-
induced QRS prolongation and attenuates associated bra-
dycardia [47,48]. A similar model exploring ILE in the
treatment of atenolol toxicity in rabbits showed no signifi-
cant changes in MAP after giving lipid [49]. While this
creates doubt about ILE use in the setting of beta blocker
intoxication, the findings may be explained by the fact that
atenolol is not nearly as lipophilic as other beta-blockers,
such as propranolol. One case report indicated hemody-
namic recovery after ILE administration in a patient with
both ethanol and atenolol intoxication. However, it cannot
be determined whether these improvements were attribu-
ted to ILE, atropine, glucagon, or saline [50].
Other Non-LA Drugs
ILE has been used as a novel treatment approach for
other toxicities, including herbacides and pesticides.
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puppy demonstrated vast reduction in recovery time
when treated with intravenous lipid over four hours
[51]. Dosing of ILE was based on therapeutic recom-
mendations for bupivacaine toxicity, as no such guide-
lines currently exist for the treatment of non-LA
toxicities. The use of ILE in treatment of a patient with
refractory hypotension caused by glyphosate-surfactant
herbicide (GlySH) has gained considerable attention
[52]. Aggressive fluid and vasopressor support did not
improve the patient’s condition, but the administration
of one lipid bolus (100 mL) and subsequent infusion
(400 mL) caused a rapid and dramatic return to normal
blood pressure. As GlySH is notoriously unresponsive to
conventional therapies, the authors suggest that ILE
should be considered in such cases of refractory hemo-
dynamic instability.
Controversies
These animal models and human case reports reveal
promising results, but also leave many questions unan-
swered. Because few animal studies have compared stan-
dard resuscitative therapies to treatment with lipid
emulsion in non-LA toxicities, future studies need to
emphasize the inclusion of ACLS-treated controls.
When patients suffer cardiac or neurologic symptoms
from local anesthetic systemic toxicity, the offending
agent (a local anesthetic) is known and ILE is a proven
resuscitative antidote. However, when patients present
in the emergency department with neurologic or cardiac
compromise there is the possibility of an unidentified
drug overdose. Should the physician administer ILE
without the knowledge of what was ingested? What if
the suspected toxin is not lipophilic? More studies and
better delineation of the mechanisms and limitations of
ILE are needed to determine best practices and clinical
guidelines for integrating use of ILE with standard
resuscitation during non-LA drug overdoses and other
potential intoxications.
Recommendations
ILE should be used in local anesthetic toxicity at the
onset of neurological or cardiovascular symptoms.
There is no known alternative antidote for the treatment
of local anesthetic toxicities resistant to standard ACLS
agents. In the setting of other lipophilic drug toxicities
causing hemodynamic compromise, when standard
resuscitation protocols are unsuccessful, clinicians can
consider administration of ILE. While protocols exist for
administration of ILE in setting of LAST, no optimal
regimen has been established to date for treatment of
acute non-LA poisonings.
Weinberg published the first recommendation for the
use of ILE in a letter to the editor in 2004 [53].
His 2006 revised version served as the basis for all sub-
sequent recommendations for ILE, including those by
the Association of Anaesthetists of Great Britain and
Ireland, the American Society of Critical Care Anesthe-
siologists, the American Society of Anesthesiologists
Committee on Critical Care Medicine, and the Resusci-
tation Council of the UK. Most recently, in spring of
2010, the American Society of Regional Anesthesia
(ASRA) published a practice advisory on local anesthetic
toxicity, highlighting lipid’s role in LAST treatment [54].
These treatment guidelines included the use of ILE as
an adjunct to airway management and good CPR, stat-
ing “...lipid emulsion therapy can be instrumental in
facilitating resuscitation, most probably by acting as a
lipid sink that draws down the content of lipid-soluble
local anesthetics from within cardiac tissue, thereby
improving cardiac conduction, contractility, and coron-
ary perfusion” [54]. A 1.5 mL/kg 20% lipid bolus with
subsequent 0.25 mL/kg/minute infusion is the currently
recommended protocol. Rebolus and increased infusion
may be considered if circulatory stability is not attained,
but 10 mL/kg lipid emulsion for 30 minutes is the
upper limit recommended for initial dosing. Also,
prompt and effective airway management must be
implemented to prevent hypoxia and respiratory acido-
sis, which may potentiate LAST [55].
While use of ILE is now commonplace for treatment
of LAST, additional clinical evidence may be needed
before ILE can be recommended as a first-line interven-
tion for non-LA overdoses [35]. Local anesthetic
induced CNS and CV disturbances are usually witnessed
events in the peri-operative environment. These events
are discovered quickly and treated expeditiously. In set-
tings such as emergency rooms, the offending drugs
must first be determined or estimated before the practi-
tioner can assess whether lipid emulsion would enhance
standard resuscitation based on relative measures of
lipophilicity.
Potential Risks of ILE
Recent reports highlight the detrimental effect that stan-
dard pharmacologic therapies might have in the setting
of lipid emulsion administration [13]. Studies by Wein-
berg et al in rat models, where bupivacaine overdose
caused asystole, showed that lipid was superior to epi-
nephrine [11], vasopressin [12] or the combination of
both when hemodynamics were measured at ten min-
utes. They postulated that severe vasoconstriction and
increased lactate levels caused by epinephrine adminis-
tration may actually exacerbate LAST. A follow up
study by Hiller et al confirmed this finding [13]. They
used a rat model to demonstrate that adding epinephr-
ine to the lipid infusion at doses above 10 mcg/kg
increased lactate concentration, worsened acidosis, and
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animals treated with lipid alone. These findings led to
the aforementioned 2010 ASRA guidelines that recom-
mend the use of low dose epinephrine, and avoiding
vasopressin completely in the setting of LAST.
The side effects of administering large doses of ILE
have been evaluated in recent safety studies. In study of
the possible pulmonary or neurological complications
following high volume 20% lipid infusions in anesthe-
tized rats, results demonstrated both normal tissue
histology and a mean LD50 of 67 mL/kg which is one
order of magnitude above typical doses [56]. The con-
clusions support the safety of lipid therapy at amounts
recommended by ASRA. It remains unclear whether
high doses of lipid could interfere with other adminis-
tered medications, but no adverse effects have been
noted in trials using ILE concomitant with sodium
bicarbonate, atropine, or calcium [43,39].
The lack of documented risks of ILE in trials and case
reports is encouraging for physicians interested in intro-
ducing this therapy to their emergency departments, but
cautious interpretation of safety data is advised. The
small sample sizes provide insufficient numbers from
which to make generalizations about rare or long-term
events. Physicians are encouraged to document all cases
of ILE utilization (both favorable and unfavorable) at
http://www.lipidregistry.org and http://www.lipidrescue.
org, as retrospective and prospective data analyses will
continue to provide insight into the scope of ILE use.
Although randomized controlled trials (RCTs) may not
be possible in this field, case reports and animal studies
s h o u l dn o ts u f f i c ea st h eo n l ys o u r c eo fi n f o r m a t i o n .
Controlled clinical trials (i.e. treatment given by experi-
mental protocols compared with standard treatment)
will be crucial for evaluating the efficacy and potential
side effects from lipid emulsion therapy.
Conclusion
Animal studies and case reports guide our current use
of ILE in treatment of both local anesthetic toxicity and
non-local anesthetic, highly lipophilic medication toxi-
city. Controlled clinical trials may be explored as a
means of comparing patient outcomes in the future. On
the whole, it seems reasonable to assume that a patient
in refractory cardiac arrest would suffer little harm if
ILE is used as a last attempt in resuscitation. Additional
research into the mechanisms of ILE in the effective
resuscitation of non-LA drug overdoses will aid the
development of clinical guidelines.
Lipid emulsion has been advocated in the resuscitation
of local anesthetic toxicity refractory to conventional
modes of resuscitation [57]. Based on review of animal
studies and the small number of case reports, ILE may
be a useful in treatment of non-LA lipophilic medication
overdoses as an adjunct to antidotal therapy and ACLS
protocols (modified to reduce vasopressor treatment).
While not yet considered a generic first-line treatment
in the setting of unknown drug overdoses, the use of
ILE should be strongly considered, particularly in failed
resuscitations. We anticipate that future animal studies
and additional case reports will help shape the evolving
recommendations for non-LA toxicities.
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